Travers Smith advises senior management team of Essential Pharma on €900 million recapitalisation
Travers Smith LLP has advised the senior management team of Essential Pharma, a global specialty pharmaceutical business focused on ensuring that patients have access to clinically differentiated, niche, branded pharmaceutical products, on the completion of a €900 million recapitalisation through a Gyrus Capital single-asset Continuation Vehicle led by AlpInvest, and a new strategic financing facility with Sixth Street.